The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis

Table 4 Median progression free survival time in the studies

Study	Median progression free survival time(months)		Median ratio	pvalue
	TS +/high	TS -/low
Bepler et al. [6]	20.7	21	1.01	0.187
Chang et al. [29]	1.3	2.4	1.85	0.407
Chen et al. [21]	3.4	4.8	1.41	0.01
Sun et al. [17]	2	4.1	2.05	0.001
Igawa et al. [30]	1.6	5.8	3.63	0.03
Pool	5.8	7.6	1.31 (95% CI 0.43-2.19)	0.13

Patients with +/high expression of TS who received pemetrexed-based chemotherapy had a median progression free survival time of 5.8 months; patients with -/low expressionof TS had a median progression free survival time of 7.6 months. Although there was a trend that TS -/low predicted better progression free survival time, the difference did not reached statistical significance (p = 0.13).

ISSN: 1471-2407